Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
Vincerx Pharma (VINC) has announced its intention to delist from Nasdaq and deregister with the SEC. The company received notice from Nasdaq on April 14, 2025, citing non-compliance with the minimum bid price requirement of $1.00 per share over 30 consecutive business days.
Trading of Vincerx's common stock was inadvertently suspended on April 16, 2025, but will resume on April 21, 2025, before being permanently suspended on April 23, 2025. The company plans to file a Form 25 for delisting around April 28, 2025.
Notably, Vincerx's board of directors has determined that dissolving, liquidating, and winding up the company's operations is in the best interest of stockholders. The company will not appeal Nasdaq's determination or seek listing on another exchange. Following the Form 25 effectiveness, Vincerx will file a Form 15 to deregister with the SEC.
Vincerx Pharma (VINC) ha annunciato la sua intenzione di ritirarsi dal Nasdaq e di cancellarsi dalla registrazione presso la SEC. La società ha ricevuto un avviso dal Nasdaq il 14 aprile 2025, che indicava il mancato rispetto del requisito minimo del prezzo di offerta di 1,00 dollari per azione per 30 giorni lavorativi consecutivi.
La negoziazione delle azioni ordinarie di Vincerx è stata sospesa per errore il 16 aprile 2025, ma riprenderà il 21 aprile 2025, per poi essere sospesa definitivamente il 23 aprile 2025. La società prevede di presentare il modulo Form 25 per il delisting intorno al 28 aprile 2025.
È importante sottolineare che il consiglio di amministrazione di Vincerx ha deciso che sciogliere, liquidare e cessare le attività dell’azienda è nel miglior interesse degli azionisti. La società non presenterà ricorso contro la decisione del Nasdaq né cercherà la quotazione su un altro mercato. Dopo l’entrata in vigore del Form 25, Vincerx presenterà il Form 15 per la cancellazione dalla registrazione presso la SEC.
Vincerx Pharma (VINC) ha anunciado su intención de retirarse del Nasdaq y cancelar su registro ante la SEC. La compañía recibió un aviso del Nasdaq el 14 de abril de 2025, citando el incumplimiento del requisito mínimo de precio de oferta de $1.00 por acción durante 30 días hábiles consecutivos.
La negociación de las acciones comunes de Vincerx fue suspendida inadvertidamente el 16 de abril de 2025, pero se reanudará el 21 de abril de 2025, antes de suspenderse de forma permanente el 23 de abril de 2025. La empresa planea presentar el Formulario 25 para la exclusión alrededor del 28 de abril de 2025.
Es importante destacar que la junta directiva de Vincerx ha determinado que disolver, liquidar y cerrar las operaciones de la compañía es lo mejor para los accionistas. La empresa no apelará la decisión del Nasdaq ni buscará cotizar en otra bolsa. Tras la efectividad del Formulario 25, Vincerx presentará el Formulario 15 para cancelar su registro ante la SEC.
Vincerx Pharma (VINC)는 나스닥에서 상장 폐지하고 SEC 등록을 취소할 계획임을 발표했습니다. 회사는 2025년 4월 14일 나스닥으로부터 30거래일 연속 주당 최소 입찰 가격 $1.00 미달로 인한 비준수 통지를 받았습니다.
Vincerx의 보통주 거래는 2025년 4월 16일 실수로 중단되었으나 2025년 4월 21일 재개되었고, 2025년 4월 23일에 영구 중단될 예정입니다. 회사는 2025년 4월 28일경 상장 폐지를 위한 Form 25를 제출할 계획입니다.
특히, Vincerx 이사회는 회사의 해산, 청산 및 사업 종료가 주주들에게 최선의 이익이라고 판단했습니다. 회사는 나스닥의 결정에 항소하지 않을 것이며 다른 거래소 상장을 추진하지도 않을 것입니다. Form 25가 효력을 발생한 후 Vincerx는 SEC 등록 취소를 위한 Form 15를 제출할 예정입니다.
Vincerx Pharma (VINC) a annoncé son intention de se retirer du Nasdaq et de radier son enregistrement auprès de la SEC. La société a reçu un avis du Nasdaq le 14 avril 2025, indiquant le non-respect de l'exigence minimale de prix d'offre de 1,00 $ par action pendant 30 jours ouvrables consécutifs.
La négociation des actions ordinaires de Vincerx a été suspendue par inadvertance le 16 avril 2025, mais reprendra le 21 avril 2025, avant d'être suspendue définitivement le 23 avril 2025. La société prévoit de déposer un formulaire 25 pour la radiation aux alentours du 28 avril 2025.
Il est à noter que le conseil d'administration de Vincerx a déterminé que dissoudre, liquider et mettre fin aux opérations de la société est dans le meilleur intérêt des actionnaires. La société ne fera pas appel de la décision du Nasdaq ni ne cherchera à être cotée sur une autre bourse. Après l'entrée en vigueur du formulaire 25, Vincerx déposera un formulaire 15 pour se radier auprès de la SEC.
Vincerx Pharma (VINC) hat seine Absicht bekannt gegeben, sich vom Nasdaq zurückzuziehen und die Registrierung bei der SEC aufzuheben. Das Unternehmen erhielt am 14. April 2025 eine Mitteilung vom Nasdaq, dass es die Mindestgebotspreisanforderung von 1,00 USD pro Aktie über 30 aufeinanderfolgende Handelstage nicht erfüllt.
Der Handel mit den Stammaktien von Vincerx wurde versehentlich am 16. April 2025 ausgesetzt, wird aber am 21. April 2025 wieder aufgenommen, bevor er am 23. April 2025 dauerhaft ausgesetzt wird. Das Unternehmen plant, um den 28. April 2025 ein Formular 25 für die Delistung einzureichen.
Bemerkenswert ist, dass der Vorstand von Vincerx beschlossen hat, dass die Auflösung, Liquidation und Abwicklung des Unternehmens im besten Interesse der Aktionäre liegt. Das Unternehmen wird gegen die Entscheidung des Nasdaq keinen Einspruch einlegen und auch keine Notierung an einer anderen Börse anstreben. Nach Wirksamwerden des Formulars 25 wird Vincerx ein Formular 15 zur Abmeldung bei der SEC einreichen.
- Shareholders will receive distribution of remaining assets after creditor payments
- Stock price fell below $1.00 minimum bid requirement
- Company to be dissolved and liquidated
- Complete delisting from public markets
- No alternative trading arrangements planned
Insights
Vincerx's announced dissolution and delisting signals terminal corporate failure with shareholders likely facing severe or total losses after creditor payments.
Vincerx Pharma's announcement represents a terminal corporate event that goes far beyond simple delisting. The board has made the definitive decision to dissolve and liquidate the entire company, not merely move to over-the-counter markets.
The company failed to maintain Nasdaq's minimum
This liquidation process entails several critical stages:
- Asset liquidation (selling all company property and IP)
- Creditor payment prioritization
- Distribution of any remaining proceeds to shareholders
Shareholders should be aware that in liquidation scenarios, creditors receive priority payment, meaning common equity holders often receive pennies on the dollar or nothing at all. The immediate trading suspension (April 23, 2025) gives shareholders an extremely narrow window to exit their positions before potential illiquidity sets in.
This development indicates comprehensive failure of the company's business model and strategy. In biotech particularly, dissolution typically occurs after clinical program failures, funding depletion, and exhaustion of all strategic alternatives including potential acquisitions or asset sales.
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025
SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (“SEC”) on or about April 28, 2025, which will remove Vincerx’s common stock from listing and registration on The Nasdaq Stock Market (“Nasdaq”).
On April 14, 2025, Vincerx received written notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of its common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of
Vincerx’s board of directors determined that it would be in the best interests of its stockholders to dissolve, liquidate, and wind-up its business and affairs and distribute to stockholders any assets remaining after paying or providing for payment of its creditors. Given this, Vincerx does not intend to appeal the Nasdaq determination. Vincerx intends to voluntarily file a Form 25 to delist and deregister its common stock. Vincerx does not intend to make arrangements to list its common stock on another national securities exchange or other market.
Once the Form 25 becomes effective, Vincerx intends to file a Form 15 to deregister with the SEC.
Trading of Vincerx’s common stock was suspended by Nasdaq inadvertently on April 16, 2025, instead of April 23, 2025, as stated in the Delisting Notice. Vincerx worked with Nasdaq to allow trading to resume at the opening of business on Monday, April 21, 2025 through April 22, 2025.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company.
Vincerx is based in San Mateo, California, and has a research facility in Monheim, Germany.
Forward-Looking Information
This press release contains forward-looking statements within the meaning of the federal securities laws including, but not limited to, statements about: Vincerx’s intent to file a Form 25 and Form 15 with the SEC and the expected timing thereof; Vincerx’s intent not to appeal Nasdaq’s determination and not to list its common stock on another national securities exchange or other market; and expectations with respect to the resuming and suspension of trading of Vincerx’s common stock on Nasdaq. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks involved in dissolving, liquidating, and winding down our business and affairs; potential effects of Nasdaq’s trading suspension, resumption, and filings of Forms 25 and 15, on the trading price, trading volume and volatility of Vincerx’s common stock; the timing or amount of distributions, if any, to Vincerx’s stockholders; the availability and sufficiency of cash to complete an orderly dissolution, liquidation, and wind-down of the Company’s business and affairs; stockholder approval of the wind-down; the Company’s ability to out-license or otherwise monetize its assets and intellectual property and the amount of cash, if any, received from such activities; the risk that Vincerx may need to seek protection of the bankruptcy court; and the other factors discussed in Vincerx’s reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Vincerx as of the date of this press release. Vincerx undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact Information:
Gabriela Jairala
Vincerx Pharma, Inc.
gabriela.jairala@vincerx.com
Totyana Simien
Inizio Evoke Comms
totyana.simien@inizioevoke.com
FAQ
When will Vincerx Pharma (VINC) be delisted from Nasdaq?
Why is Vincerx Pharma (VINC) being delisted from Nasdaq?
What happens to VINC shareholders after the delisting?
Will Vincerx (VINC) stock trade on another exchange after Nasdaq delisting?
